Education
About Us
Working with TipRanks
Follow Us
Dr. Hoenle AG (DE:HNL)
XETRA:HNL
See the Price Targets and Ratings of:
HNL Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
€8
Hold
-4.31%
Downside
Reiterated
08/06/25
Dr. Hoenle AG's stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company's declining revenues and profitability issues are significant concerns, compounded by negative valuation metrics. Technical analysis suggests further downside potential, with the stock trading below key moving averages and showing oversold conditions. The absence of earnings call data and corporate events means these factors do not influence the score.
Warburg Research
€22
Buy
163.16%
Upside
Reiterated
11/22/24
We assume that goodwill amortisation will amount to EUR 7-8m and are hence attributing the vast majority to the write-downs. At the end of FY 2023, Hönle had goodwill of EUR 18m in its balance sheet. Of this roughly EUR 6m can be attributed to Hoenle AG and Raesch Malta respectively and another EUR 5m to Sterilsystems. As the disinfection business is not expected to be affected by the measures, the sources of the goodwill amortisation are expected to have been Hoenle AG, with its higher exposure to printing customers, and Raesch Malta, where profitability has been stable but at low levels. Organically, Hönle reached sales of EUR 98m and a slightly positive EBIT in FY 2024, which is in line with the expectation. The operating development is expected to have troughed in the last FY.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
€8
Hold
-4.31%
Downside
Reiterated
08/06/25
Dr. Hoenle AG's stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company's declining revenues and profitability issues are significant concerns, compounded by negative valuation metrics. Technical analysis suggests further downside potential, with the stock trading below key moving averages and showing oversold conditions. The absence of earnings call data and corporate events means these factors do not influence the score.
Warburg Research
€22
Buy
163.16%
Upside
Reiterated
11/22/24
We assume that goodwill amortisation will amount to EUR 7-8m and are hence attributing the vast majority to the write-downs. At the end of FY 2023, Hönle had goodwill of EUR 18m in its balance sheet. Of this roughly EUR 6m can be attributed to Hoenle AG and Raesch Malta respectively and another EUR 5m to Sterilsystems. As the disinfection business is not expected to be affected by the measures, the sources of the goodwill amortisation are expected to have been Hoenle AG, with its higher exposure to printing customers, and Raesch Malta, where profitability has been stable but at low levels. Organically, Hönle reached sales of EUR 98m and a slightly positive EBIT in FY 2024, which is in line with the expectation. The operating development is expected to have troughed in the last FY.
Best Analysts Covering Dr. Hoenle AG
1 Month
xxx
Success Rate
13/19 ratings generated profit
Average Return
+4.29%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.42% of your transactions generating a profit, with an average return of +4.29% per trade.
3 Months
xxx
Success Rate
8/19 ratings generated profit
Average Return
+2.07%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of +2.07% per trade.
1 Year
Success Rate
8/19 ratings generated profit
Average Return
-11.92%
reiterated a buy rating 9 months ago
Copying Malte Schaumann's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of -11.92% per trade.
2 Years
xxx
Success Rate
0/19 ratings generated profit
Average Return
-34.14%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -34.14% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HNL Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
1
0
0
0
Buy
0
0
0
0
0
Hold
2
4
7
9
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
5
7
9
9
Each month's total comprises the sum of three months' worth of ratings.
HNL Stock Forecast FAQ
What is DE:HNL’s average 12-month price target, according to analysts?
Based on analyst ratings, Dr. Hoenle AG’s 12-month average price target is 10.00.
What is DE:HNL’s upside potential, based on the analysts’ average price target?
Dr. Hoenle AG has 19.62% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Dr. Hoenle AG a Buy, Sell or Hold?
Dr. Hoenle AG has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Dr. Hoenle AG’s share price target?
The average share price target for Dr. Hoenle AG is 10.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €10.00 ,and the lowest forecast is €10.00. The average share price target represents 19.62% Increase from the current price of €8.36.
The highest analyst share price target is €10.00 ,and the lowest forecast is €10.00. The average share price target represents 19.62% Increase from the current price of €8.36.
What do analysts say about Dr. Hoenle AG?
Dr. Hoenle AG’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of Dr. Hoenle AG?
To buy shares of DE:HNL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.